EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Engineering Mycobacterium smegmatis to produce oxygenic mycolic acids of Mycobacterium tuberculosis

Udipta Bohara, Liwu Li, Biswarup Mukhopadhyay, Endang Purwantini

Frontiers in Chemical Biology · 19.06.2026 · 5

DOI: 10.3389/fchbi.2026.1809486 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Chemical Biology, online erschienen am 19.06.2026. Verfasst von Udipta Bohara und 3 weiteren Autor:innen. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mycolic acids (MAs), which are β-hydroxy fatty acids with long alpha-alkyl side chains, are major components of the cell wall of Mycobacterium tuberculosis ( Mtb ), which causes tuberculosis. These lipids also occur in M. tuberculosis var bovis BCG ( Bacillus Calmette-Guérin), a vaccine strain. Ongoing research, that followed observations on the off-target beneficial effects of BCG vaccination has raised a possibility that methoxy- and keto-derivatives of MAs (M-MAs and K-MAs) may help to train human innate immune cells to combat and prevent sepsis, a life-threatening condition resulting from uncontrolled spread of microbial and viral infections. To allow facile testing of this possibility, we have developed methods for the generation of M-MAs and K-MAs without using Mtb, a pathogen, or BCG, which grows slowly. We have developed methods for facile production of substantial amounts of M-MAs and K-MAs by engineering Mycobacterium smegmatis ( Msm ) , a non-pathogenic and fast-growing organism, to express MA-oxygenation genes from Mtb , and purifying these MAs from the recombinant strains (approximately 70 mg from a 100 mL culture); the authenticities of the products were confirmed via mass spectrometry. The system could also provide additional oxygenated MAs, epoxy- and hydroxy-derivatives. This advancement will help to interrogate the possible application of oxygenated mycolic acids in treating sepsis in humans with a manageable cost and relative ease. This applied study has also provided leads for foundational studies on how individual oxygenation and cyclopropanation system influences each other in terms of product formation.

Zitieren

APA

Bohara, U., Li, L., Mukhopadhyay, B., & Purwantini, E. (2026). Engineering Mycobacterium smegmatis to produce oxygenic mycolic acids of Mycobacterium tuberculosis. Frontiers in Chemical Biology, 5. https://doi.org/10.3389/fchbi.2026.1809486

Vancouver

Bohara U, Li L, Mukhopadhyay B, Purwantini E. Engineering Mycobacterium smegmatis to produce oxygenic mycolic acids of Mycobacterium tuberculosis. Frontiers in Chemical Biology. 2026;5. doi:10.3389/fchbi.2026.1809486

BibTeX
@article{Bohara2026,
  author = {Bohara, Udipta and Li, Liwu and Mukhopadhyay, Biswarup and Purwantini, Endang},
  title = {Engineering Mycobacterium smegmatis to produce oxygenic mycolic acids of Mycobacterium tuberculosis},
  journal = {Frontiers in Chemical Biology},
  year = {2026},
  volume = {5},
  doi = {10.3389/fchbi.2026.1809486}
}
Kostenlos starten →